Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity

Tadashi Hanafusa, Ali E A Mohamed, Shohei Domae, Eiichi Nakayama, Toshiro Ono

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Identification of new cancer antigens is necessary for the efficient diagnosis and immunotherapy. A variety of tumor antigens have been identified by several methodologies. Among those antigens, cancer/testis (CT) antigens have became promising targets.Methods: The serological identification of antigens by the recombinant expression cloning (SEREX) methodology has been successfully used for the identification of cancer/testis (CT) antigens. We performed the SEREX analysis of colon cancer.Results: We isolated a total of 60 positive cDNA clones comprising 38 different genes. They included 2 genes with testis-specific expression profiles in the UniGene database, such as TEKT5 and a CT-like gene, A kinase anchoring protein 3 (AKAP3). Quantitative real-time RT-PCR analysis showed that the expression of TEKT5 was restricted to the testis in normal adult tissues. In malignant tissues, TEKT5 was aberrantly expressed in a variety of cancers, including colon cancer. A serological survey of 101 cancer patients with different cancers by ELISA revealed antibodies to TEKT5 in 13 patients, including colon cancer. None of the 16 healthy donor serum samples were reactive in the same test.Conclusion: We identified candidate new CT antigen of colon cancer, TEKT5. The findings indicate that TEKT5 is immunogenic in humans, and suggest its potential use as diagnostic as well as an immunotherapeutic reagent for cancer patients.

Original languageEnglish
Article number520
JournalBMC Cancer
Volume12
DOIs
Publication statusPublished - Nov 14 2012

Fingerprint

Testicular Neoplasms
Colonic Neoplasms
Antigens
Testis
Neoplasms
Genes
Neoplasm Antigens
Immunotherapy
Protein Kinases
Organism Cloning
Real-Time Polymerase Chain Reaction
Complementary DNA
Clone Cells
Enzyme-Linked Immunosorbent Assay
Tissue Donors
Databases
Antibodies
Serum

Keywords

  • CT antigen
  • SEREX
  • TEKT5

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity. / Hanafusa, Tadashi; Mohamed, Ali E A; Domae, Shohei; Nakayama, Eiichi; Ono, Toshiro.

In: BMC Cancer, Vol. 12, 520, 14.11.2012.

Research output: Contribution to journalArticle

Hanafusa, Tadashi ; Mohamed, Ali E A ; Domae, Shohei ; Nakayama, Eiichi ; Ono, Toshiro. / Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity. In: BMC Cancer. 2012 ; Vol. 12.
@article{6ebcd899cc9f461d80cb806dcf9a02ea,
title = "Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity",
abstract = "Background: Identification of new cancer antigens is necessary for the efficient diagnosis and immunotherapy. A variety of tumor antigens have been identified by several methodologies. Among those antigens, cancer/testis (CT) antigens have became promising targets.Methods: The serological identification of antigens by the recombinant expression cloning (SEREX) methodology has been successfully used for the identification of cancer/testis (CT) antigens. We performed the SEREX analysis of colon cancer.Results: We isolated a total of 60 positive cDNA clones comprising 38 different genes. They included 2 genes with testis-specific expression profiles in the UniGene database, such as TEKT5 and a CT-like gene, A kinase anchoring protein 3 (AKAP3). Quantitative real-time RT-PCR analysis showed that the expression of TEKT5 was restricted to the testis in normal adult tissues. In malignant tissues, TEKT5 was aberrantly expressed in a variety of cancers, including colon cancer. A serological survey of 101 cancer patients with different cancers by ELISA revealed antibodies to TEKT5 in 13 patients, including colon cancer. None of the 16 healthy donor serum samples were reactive in the same test.Conclusion: We identified candidate new CT antigen of colon cancer, TEKT5. The findings indicate that TEKT5 is immunogenic in humans, and suggest its potential use as diagnostic as well as an immunotherapeutic reagent for cancer patients.",
keywords = "CT antigen, SEREX, TEKT5",
author = "Tadashi Hanafusa and Mohamed, {Ali E A} and Shohei Domae and Eiichi Nakayama and Toshiro Ono",
year = "2012",
month = "11",
day = "14",
doi = "10.1186/1471-2407-12-520",
language = "English",
volume = "12",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity

AU - Hanafusa, Tadashi

AU - Mohamed, Ali E A

AU - Domae, Shohei

AU - Nakayama, Eiichi

AU - Ono, Toshiro

PY - 2012/11/14

Y1 - 2012/11/14

N2 - Background: Identification of new cancer antigens is necessary for the efficient diagnosis and immunotherapy. A variety of tumor antigens have been identified by several methodologies. Among those antigens, cancer/testis (CT) antigens have became promising targets.Methods: The serological identification of antigens by the recombinant expression cloning (SEREX) methodology has been successfully used for the identification of cancer/testis (CT) antigens. We performed the SEREX analysis of colon cancer.Results: We isolated a total of 60 positive cDNA clones comprising 38 different genes. They included 2 genes with testis-specific expression profiles in the UniGene database, such as TEKT5 and a CT-like gene, A kinase anchoring protein 3 (AKAP3). Quantitative real-time RT-PCR analysis showed that the expression of TEKT5 was restricted to the testis in normal adult tissues. In malignant tissues, TEKT5 was aberrantly expressed in a variety of cancers, including colon cancer. A serological survey of 101 cancer patients with different cancers by ELISA revealed antibodies to TEKT5 in 13 patients, including colon cancer. None of the 16 healthy donor serum samples were reactive in the same test.Conclusion: We identified candidate new CT antigen of colon cancer, TEKT5. The findings indicate that TEKT5 is immunogenic in humans, and suggest its potential use as diagnostic as well as an immunotherapeutic reagent for cancer patients.

AB - Background: Identification of new cancer antigens is necessary for the efficient diagnosis and immunotherapy. A variety of tumor antigens have been identified by several methodologies. Among those antigens, cancer/testis (CT) antigens have became promising targets.Methods: The serological identification of antigens by the recombinant expression cloning (SEREX) methodology has been successfully used for the identification of cancer/testis (CT) antigens. We performed the SEREX analysis of colon cancer.Results: We isolated a total of 60 positive cDNA clones comprising 38 different genes. They included 2 genes with testis-specific expression profiles in the UniGene database, such as TEKT5 and a CT-like gene, A kinase anchoring protein 3 (AKAP3). Quantitative real-time RT-PCR analysis showed that the expression of TEKT5 was restricted to the testis in normal adult tissues. In malignant tissues, TEKT5 was aberrantly expressed in a variety of cancers, including colon cancer. A serological survey of 101 cancer patients with different cancers by ELISA revealed antibodies to TEKT5 in 13 patients, including colon cancer. None of the 16 healthy donor serum samples were reactive in the same test.Conclusion: We identified candidate new CT antigen of colon cancer, TEKT5. The findings indicate that TEKT5 is immunogenic in humans, and suggest its potential use as diagnostic as well as an immunotherapeutic reagent for cancer patients.

KW - CT antigen

KW - SEREX

KW - TEKT5

UR - http://www.scopus.com/inward/record.url?scp=84868705063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868705063&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-12-520

DO - 10.1186/1471-2407-12-520

M3 - Article

C2 - 23151147

AN - SCOPUS:84868705063

VL - 12

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 520

ER -